Medical Nanotechnology Department, Advanced Technologies Faculty, Iran University of Medical Sciences, Tehran, Iran.
Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran.
J Biomater Sci Polym Ed. 2023 Oct;34(13):1793-1812. doi: 10.1080/09205063.2023.2187204. Epub 2023 Mar 20.
Reducing intraocular pressure (IOP) with eye drops is one of the most common ways to control glaucoma. Low bioavailability and high frequency of administration in eye drops are major challenges in ocular pharmacotherapy. Contact lenses have attracted the attention of scientists in recent decades as an alternative method. In this study, with the aim of long-term drug delivery and better patient compatibility, contact lenses with surface modification and nanoparticles were used. In this study, timolol-maleate was loaded into polymeric nanoparticles made of chitosan conjugate with lauric acid and sodium alginate. Then silicon matrix was mixed with a curing agent (10:1), and the suspension of nanoparticles was added to the precursor and cured. Finally, for surface modification, the lenses were irradiated with oxygen plasma at different exposure times (30, 60, and 150 s) and soaked in different BSA concentrations (1, 3, and 5% w/v). The results showed nanoparticles with a size of 50 nm and a spherical shape were synthesized. The best surface modification of the lenses was for 5 (% w/v) albumin concentration and 150 s exposure time, which had the highest increase in hydrophilicity. Drug release from nanoparticles continued for 3 days and this amount increased to 6 days after dispersion in the modified lens matrix. The drug model and kinetic study show the Higuchi model completely supported the release profile. This study represents the novel drug delivery system to control intra-ocular pressure as a candidate platform for glaucoma treatment. Improved compatibility and drug release from the designed contact lenses would prepare new insight into the mentioned disease treatment.
通过眼药水降低眼内压 (IOP) 是控制青光眼最常见的方法之一。眼部药物治疗中存在生物利用度低和滴眼频率高的主要挑战。接触镜作为一种替代方法,近年来引起了科学家的关注。在这项研究中,为了实现长期药物输送和更好的患者兼容性,使用了经过表面修饰和纳米颗粒处理的接触镜。在这项研究中,马来酸噻吗洛尔被装载到由壳聚糖与月桂酸和海藻酸钠的缀合物制成的聚合物纳米颗粒中。然后将硅基质与固化剂(10:1)混合,将纳米颗粒悬浮液加入前体中并固化。最后,为了进行表面修饰,将镜片用不同暴露时间(30、60 和 150 秒)的氧气等离子体照射,并在不同的 BSA 浓度(1、3 和 5%w/v)下浸泡。结果表明,合成了粒径为 50nm、呈球形的纳米颗粒。镜片的最佳表面修饰条件为 5%(w/v)白蛋白浓度和 150 秒暴露时间,其亲水性提高最大。纳米颗粒的药物释放持续了 3 天,在修饰后的镜片基质中分散后,该释放量增加到 6 天。药物模型和动力学研究表明,Higuchi 模型完全支持释放曲线。这项研究代表了一种新型的药物输送系统,可作为治疗青光眼的候选平台来控制眼内压。设计的接触镜具有更好的相容性和药物释放,为治疗上述疾病提供了新的思路。